Antengene Corporation Limited presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2021, which demonstrated the synergistic effect of the combination of ATG-010 (selinexor, XPO1 inhibitor) and ATG-008 (onatasertib, mTORC1/2 inhibitor) for the treatment of triple-hit diffuse large B-cell lymphoma (DLBCL). Results from this study demonstrated potent in vitro and in vivo anti-tumor efficacy and synergy with the combination of ATG-010 and ATG-008, including strong synergistic activities in the triple-hit DLBCL cell line. Meanwhile, in the DLBCL circulating tumor cell-derived explants (CDX) model, the combination of ATG-010 and ATG-008 also showed enhanced tumor growth inhibition and synergism. The single agent oral XPO1 inhibitor, ATG-010, is a first-in-class and only-in-class selective inhibitor of nuclear export (SINE) compound, approved by the US Food and Drug Administration (FDA) for the treatment of patients with DLBCL after at least two prior therapies. ATG-008 is a dual mTORC1/2 kinase inhibitor, which has shown preclinical and clinical activity in treating DLBCL. Antengene is currently developing a clinical study to investigate the combination of ATG-010 and ATG-008 in relapsed or refractory DLBCL (the MATCH trial). The preclinical data showed: ATG-008 and ATG-010 both inhibit the growth of the DLBCL cell line in vitro; ATG-008 combined with ATG-010 enhanced the growth inhibition of triple-hit DLBCL cells; ATG-008 combined with ATG-010 showed in vitro synergism in triple-hit DLBCL cells; ATG-008 combined with ATG-010 showed in vivo synergism in CDX of the triple-hit DLBCL cell line.